Research index

Browse research by topic

Every research article on Weight Loss Rankings, grouped by theme. Each cluster is a curated index of related primary- source investigations — start with the topic that matches your question.

GLP-1s for Cardiovascular & Comorbidity Outcomes

How GLP-1 receptor agonists affect cardiovascular events, heart failure, kidney disease, sleep apnea, and other comorbidities — anchored in the SELECT, FLOW, STEP-HFpEF, and SURMOUNT-OSA trials.

8 articles

GLP-1 Safety, Side Effects & Stopping Safely

Trial-anchored answers to the most-searched safety questions about Wegovy, Ozempic, Zepbound, Mounjaro, and Foundayo — including thyroid cancer risk, liver effects, surgery prep, and what happens after stopping.

10 articles

GLP-1 Pricing 2026: Insurance, Brand-Name, Compounded & Oral Options

What GLP-1s actually cost in 2026 across insurance plans, brand-name pens, compounded telehealth, and the new oral option — plus practical guidance on how to get a prescription.

10 articles

Compounded GLP-1s: Bioequivalence, Pharmacy Standards & Safety

The regulatory and quality picture for compounded semaglutide and tirzepatide — bioequivalence research, FDA enforcement actions, PCAB pharmacy accreditation, and reconstitution math.

5 articles

GLP-1 Dosing, Injection Technique & Pharmacokinetics

Practical patient questions about how to use GLP-1s safely — injection technique, dose conversion, storage, travel, microdosing, switching between drugs, and how the new oral GLP-1 (Foundayo) is taken.

10 articles

GLP-1 Drug Comparisons & Pipeline: Wegovy, Zepbound, Foundayo & Beyond

Side-by-side comparisons of every approved and pipeline GLP-1 — semaglutide vs tirzepatide, the new oral orforglipron (Foundayo), CagriSema, retatrutide, survodutide, and the rest of the 2026-2028 pipeline.

12 articles

GLP-1 Lifestyle, Body Composition & Long-Term Outcomes

Evidence-based guidance on nutrition, exercise, lean mass preservation, plateaus, alcohol use disorder, antidepressant interactions, and the long-term lifestyle picture on GLP-1 therapy.

11 articles